Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial (Q41489870)

1 October 2017

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial (English)

1 reference

1 October 2017

0 references

0 references

0 references

0 references

J W Murrough

1

1 reference

1 October 2017

L Soleimani

2

1 reference

1 October 2017

K E DeWilde

3

1 reference

1 October 2017

K A Collins

4

1 reference

1 October 2017

K A Lapidus

5

1 reference

1 October 2017

B M Iacoviello

6

1 reference

1 October 2017

M Lener

7

1 reference

1 October 2017

M Kautz

8

1 reference

1 October 2017

J Kim

9

1 reference

1 October 2017

J B Stern

10

1 reference

1 October 2017

R B Price

11

1 reference

1 October 2017

A M Perez

12

1 reference

1 October 2017

J W Brallier

13

1 reference

1 October 2017

G J Rodriguez

14

1 reference

1 October 2017

W K Goodman

15

1 reference

1 October 2017

D V Iosifescu

16

1 reference

1 October 2017

D S Charney

17

1 reference

1 October 2017

language of work or name

English

0 references

publication date

12 August 2015

1 reference

1 October 2017

Psychological Medicine

1 reference

1 October 2017

45

1 reference

1 October 2017

3571-3580

1 reference

1 October 2017

16

1 reference

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

1 October 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Psychological autopsy studies of suicide: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Familial transmission of suicidal behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Ketamine as a novel antidepressant: from synapse to behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Mental health: A road map for suicide research and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Ketamine for treatment-resistant unipolar depression: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Suicide prevention strategies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

The medical management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A randomized controlled trial of intranasal ketamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

BDNF promoter methylation and suicidal behavior in depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Existing and novel biological therapeutics in suicide prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Connecting inflammation with glutamate agonism in suicidality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Suicide brain is associated with decreased expression of neurotrophins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Synaptic dysfunction in depression: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Leading causes of unintentional and intentional injury mortality: United States, 2000-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Scale for Suicide Ideation: psychometric properties of a self-report version

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Basic dimensions of change in the symptomatology of chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

Neurobiology of suicidal behaviour

1 reference

https://api.crossref.org/works/10.1017%2FS0033291715001506

7 January 2021

10.1017/S0033291715001506

Identifiers

DOI

1 reference

1 October 2017

1 reference